EUCTR2013-002818-12-ES进行中（未招募）1 期
A phase III, randomized, open-label, 500-subject clinical trial of minimally invasive surgery plus rt-PA in the treatment of intracerebral haemorrhage. - Minimally invasive surgery for ICH (MISTIE III)
The John Hopkins University0 个研究点目标入组 499 人开始时间: 2014年8月6日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 499
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1)Spontaneous supratentorial ICH ? 30 mL diagnosed using radiographic imaging (CT, CTA, etc.), with a GCS ? 14 or a NIHSS ? 6.
- •Six-hour clot size equal to the most previous clot size (within 5 mL) as determined by additional CT scans at least 6 hours apart using the ABC/2 method.
- •2)Symptoms less than 24 hours prior to diagnostic CT (dCT) scan (an unknown time of onset is exclusionary).
- •3)Intention to initiate surgery between 12 and 72 hours after dCT. First dose can be given within 76 hours after dCT (delays for post surgical stabilization of catheter bleeding or because of unanticipated surgical delay are acceptable with approved waiver from the CCC).
- •4)SBP < 180 mmHg sustained for six hours recorded closest to the time of randomization.
- •5)Historical Rankin score of 0 or 1.
- •6)Age ? 18 and ? 80.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 250
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 250
排除标准
- •1)Infratentorial hemorrhage.
- •Intraventricular hemorrhage requiring treatment with extraventricular drainage (obstruction of third and fourth ventricles).
- •Thalamic bleeds with apparent midbrain extension with third nerve palsy or dilated and non-reactive pupils. Other (supranuclear) gaze abnormalities are not exclusions. Note: Patients with a posterior fossa ICH or cerebellar hematomas are ineligible.
- •Irreversible impaired brain stem function (bilateral fixed, dilated pupils and extensor motor posturing), GCS ? 4.
- •Ruptured aneurysm, arteriovenous malformation (AVM), vascular anomaly, Moyamoya disease diagnosed with radiographic imaging.
- •Patients with unstable mass or evolving intracranial compartment syndrome.
- •2)Platelet count < 100,000, INR > 1.4, or an elevated prothrombin time (PT) or activated partial thromboplastin time (aPTT).
- •Any irreversible coagulopathy or known clotting disorder.
- •Inability to sustain INR ? 1.4 using short- and long-active procoagulants (such as but not limited to NovoSeven, FFP, and/or vitamin K).
- •Subjects requiring long-term anti-coagulation are excluded. Reversal of anticoagulation is permitted for medically stable patients who can realistically tolerate the short term risk of reversal. Patient must not require Coumadin (anticoagulation) during the first 30 days, and normalized coagulation parameters must be demonstrated, monitored closely and maintained during the period of brain instrumentation.
- •Use of Dabigatran prior to symptom onset.
- •3)Internal bleeding, involving retroperitoneal sites, or the gastrointestinal, genitourinary, or respiratory tracts.
- •4)Superficial or surface bleeding, observed mainly at vascular puncture and access sites (e.g., venous cutdowns, arterial punctures, etc.) or site of recent surgical intervention.
- •5)Positive urine or serum pregnancy test in pre-menopausal female subjects without a documented history of surgical sterilization.
- •6)Allergy/sensitivity to rt-PA.
- •Prior enrollment in the study.
- •Planned or simultaneous participation (between screening and Day-30) in another interventional medical investigation or clinical trial. Patients in observational, natural history, and/or epidemiological studies not involving an intervention are eligible.
- •7)Subjects who are not expected to survive to the day 365 visit due to co-morbidities and/or are DNR/DNI status prior to randomization are excluded.
- •Any concurrent serious illness that would interfere with the safety assessments including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, immunologic, and hematologic disease.
- •Patients with a mechanical heart valve.
- •Known risk for embolization, including history of left heart thrombus, mitral stenosis with atrial fibrillation, acute pericarditis, or subacute bacterial endocarditis.
- •Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated.
- •8)Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
研究者
相似试验
进行中（未招募）
1 期
MISTIE III. A phase III, randomized, case-controlled, open-label, 500-subject clinical trial of minimally invasive surgery plus rt-PA in the treatment of intracerebral hemorrhage.Spontaneous supratentorial intracerebral haemorrhageMedDRA version: 18.0 Level: PT Classification code 10062025 Term: Intracerebral haematoma evacuation System Organ Class: 10042613 - Surgical and medical proceduresEUCTR2013-002818-12-GBThe John Hopkins University499
进行中（未招募）
1 期
MISTIE III. A phase III, randomized, case-controlled, open-label, 500-subject clinical trial of minimally invasive surgery plus rt-PA in the treatment of intracerebral hemorrhage.EUCTR2013-002818-12-HUThe John Hopkins University499
进行中（未招募）
1 期
MISTIE III. A phase III, randomized, case-controlled, open-label, 500-subject clinical trial of minimally invasive surgery plus rt-PA in the treatment of intracerebral hemorrhage.Spontaneous supratentorial intracerebral haemorrhageMedDRA version: 19.1Level: PTClassification code 10062025Term: Intracerebral haematoma evacuationSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2013-002818-12-DEThe John Hopkins University499
招募中
3 期
Study of efficacy of capmatinib in comparison with standard of care docetaxel as a second or third line therapy in participants with non-small cell lung cancers harboring MET exon 14 skipping mutation.CTRI/2020/09/027575ovartis Healthcare Pvt Ltd
已完成
3 期
A phase III, randomized, controlled, open-label, multicenter, global study of capmatinib versus SoC docetaxel chemotherapy in previously treated patients with EGFR wt, ALK negative, locally advanced or metastatic (stage IIIB/IIIC or IV) NSCLC harboring MET exon 14 skipping mutation (MET*ex14)non small cell lung cancer with a C-MET mutation10038666NL-OMON52922ovartis4